Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (0683-095 AMJ)

This study is ongoing, but not recruiting participants.

Study NCT00773838 Information provided by Merck

First Received: October 14, 2008 Last Updated: September 7, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	April 2012
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)